Atacama Labs Oy Appoints Dr. Robert Lammens as Chief Technology Officer
announced the appointment of Dr.
Dr. Lammens is responsible for the further development of the company’s
proprietary Pneumatic Dry Granulation technology, PDG Technology(TM). Dr
Lammens also develops the company’s own product portfolio and supports
clients in developing pharmaceutical products with the PDG Technology(TM).
“The appointment of Dr. Lammens strengthens our scientific and technical
capabilities significantly. The combination of his knowledge and our unique
PDG Technology(TM) is an enormous opportunity for Atacama and our customers.
Dr Lammens’ proven track record in development of pharmaceutical processes
will raise Atacama to the next level,” said Mr.
the Board of Directors, Atacama Labs Oy.
Pharmaceutical Technology, especially in dry granulation. He has received his
Ph.D. in the field of Pharmaceutical Technology from the University of Leiden
he worked for 23 years mainly in the field of solid dosage forms. In addition
to his new position as the CTO of Atacama Labs, he will continue as Senior
Lecturer at the Department of Pharmaceutical Technology of University of
Bonn, where he is coaching several Ph.D. projects in the field of granulation
and tableting in close cooperation with the director of this department,
Processengineering AG, the leading compactor vendor in the world
About Atacama Labs Oy
Atacama Labs Oy is a privately owned specialty pharmaceutical company
- galenic development from test granulations to full galenic development - contract manufacturing services from tablets to fully packaged products. The company is located in Helsinki, Finland.
SOURCE Atacama Labs Oy